Non Alcoholic Fatty Liver Disease Nafld clinical trials

Explore recruiting non alcoholic fatty liver disease nafld clinical trials.

Recruiting non alcoholic fatty liver disease nafld studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Alcoholic Fatty Liver Disease Nafld trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Romania, Bulgaria, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

Poland, Belgium, Austria, Hungary, Italy, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis

Sweden, Spain, Denmark, Italy, Norway, Portugal

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Alcoholic Fatty Liver Disease Nafld trials by city

Non Alcoholic Fatty Liver Disease Nafld in Toronto Non Alcoholic Fatty Liver Disease Nafld in Vancouver Non Alcoholic Fatty Liver Disease Nafld in Montreal Non Alcoholic Fatty Liver Disease Nafld in Calgary Non Alcoholic Fatty Liver Disease Nafld in Edmonton Non Alcoholic Fatty Liver Disease Nafld in Ottawa Non Alcoholic Fatty Liver Disease Nafld in Winnipeg Non Alcoholic Fatty Liver Disease Nafld in Quebec City Non Alcoholic Fatty Liver Disease Nafld in Hamilton Non Alcoholic Fatty Liver Disease Nafld in Kitchener Non Alcoholic Fatty Liver Disease Nafld in London Non Alcoholic Fatty Liver Disease Nafld in Halifax Non Alcoholic Fatty Liver Disease Nafld in New York Non Alcoholic Fatty Liver Disease Nafld in Los Angeles Non Alcoholic Fatty Liver Disease Nafld in Chicago Non Alcoholic Fatty Liver Disease Nafld in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease